# Project completion report

## Objective

Build a simple-to-explain, GitHub-ready AI portfolio tool that uses public cancer pharmacogenomic data and XGBoost to predict preclinical drug response while showing uncertainty and failure modes.

## Completed milestones

1. Reproducible Python package and configuration.
2. Release-tolerant DepMap Public 26Q1 ingestion.
3. Real PRISM response audit and five-drug scope.
4. Multimodal integration of expression, damaging mutations, hotspot mutations, copy number, genomic signatures and lineage.
5. Grouped leakage-safe splits and training-only feature selection.
6. Naive, lineage-only, Elastic Net and XGBoost baselines/models.
7. Probability calibration, validation-selected threshold, conformal intervals and OOD detection.
8. Five-fold out-of-fold validation.
9. Frozen GDSC2 external validation and assay-concordance analysis.
10. SHAP, feature stability, modality ablation and lineage holdout.
11. Python API, CLI, Streamlit, tests, CI and Docker definitions.
12. Real examples, non-expert README, technical documentation, wheel and clean release ZIP.

## Final scientific position

- Trametinib and afatinib are the strongest validated portfolio demonstrations.
- Palbociclib contains biologically plausible signal but weak strict external transfer.
- Olaparib and gemcitabine are transparent weak/negative outcomes.
- No result is presented as a patient-treatment prediction.

## Deliverable boundary

The GitHub release contains code, compact real model bundles, examples, validation predictions, metrics, figures and provenance manifests. Large original DepMap/PRISM/GDSC2 files and the 248 MB processed feature matrix are intentionally omitted and can be reconstructed from official sources.
